Fig. 4
From: The use of autologous platelet-rich plasma in embryo culture to obtain high-quality embryos
Comparison of stage-specific usable and high-grade embryo ratios between previous and PRP-added groups in groups II and IV according to the POSEIDON criteria (The shaded and pattern-filled bar graph represents the PRP-added group. ***p < 0.001, **p < 0.01). (A) Total usable embryo rate in POSEIDON group II showed higher numbers in PRP-added group (19.6% in the PRP-added group vs. 15.3% in the previous group, p = 0.027). (B–C) Usable embryo rate at the cleavage stage in POSEIDON group II was significantly lower. Usable and high-grade embryo rates according to embryo stage in POSEIDON group II were also showing significant improvements at the blastocyst stage (usable embryo rates in PRP-added group vs. previous group; 26.3% vs. 53.1% in cleavage stage, p = 0.001; 27.8% vs. 28.1% in morula stage, p = 0.959; 45.9% vs. 18.8% in blastocyst stage, p = 0.001; high-grade embryo rates in PRP-added group vs. previous group; 6.0% vs. 6.3% in cleavage stage, p = 0.942; 15.0% vs. 8.3% in morula stage, p = 0.126; 39.1% vs. 16.7% in blastocyst stage, p = 0.001). (D) Furthermore, comparison of total usable embryo rate in POSEIDON group IV was higher in PRP-added group (23.9% in the PRP-added group vs. 15.8% in the previous group, p = 0.020). (E) Usable embryo rates according to embryo stage in POSEIDON group IV. In the PRP group, the ratio of usable embryo was significantly lower at the cleavage stage and significantly higher at the morula stage (PRP-added group vs. previous group; 26.3% vs. 58.1% in cleavage stage, p = 0.001; 29.8% vs. 16.0% in morula stage, p = 0.013; 43.9% vs. 56.0% in blastocyst stage, p = 0.251). (F) High-grade embryo rates according to embryo stage in POSEIDON group IV did not show statistically significant differences at all stages. However, in the PRP group, there was a decreasing trend at the cleavage stage and an increasing trend at the morula and blastocyst stages (PRP-added group vs. previous group; 12.3% vs. 25.6% in cleavage stage, p = 0.087; 19.3% vs. 7.0% in morula stage, p = 0.079; 42.1% vs. 25.6% in blastocyst stage, p = 0.086).
